DBI (diazepam binding inhibitor (GABA receptor modulator, acyl-CoA binding protein) ) Blocking Peptide (the N terminal of DBI)(100ug)

Supplier: Aviva Systems Biology Incorporated

0 reviews | Write a Review Pencil

Description
Additional Information

This is a synthetic peptide designed for use in combination with anti-DBI Antibody (ARP32803_P050), made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.

Reactivities:	Human
Presku:	AAP32803
Size:	100ug
Weight:	12kDa
Gene:	The peptide is characterized by mass spectroscopy
Format:	Lyophilized powder
Target:	DBI is diazepam binding inhibitor. The protein that is regulated by hormones and is involved in lipid metabolism and the displacement of beta-carbolines and benzodiazepines, which modulate signal transduction at type A gamma-aminobutyric acid receptors located in brain synapses. DBI is conserved from yeast to mammals, with the most highly conserved domain consisting of seven contiguous residues that constitute the hydrophobic binding site for medium- and long-chain acyl-Coenzyme A esters. Diazepam binding inhibitor is also known to mediate the feedback regulation of pancreatic secretion and the postprandial release of cholecystokinin, in addition to its role as a mediator in corticotropin-dependent adrenal steroidogenesis. Three pseudogenes located on chromosomes 6, 8 and 16 have been identified. Multiple transcript variants encoding different isoforms have been described for this gene.
Alternative names:	ACBD1; ACBP; CCK-RP; EP; MGC70414